DOP82 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab073.121
Abstract: Filgotinib (FIL) is a once-daily, oral, preferential Janus kinase 1 inhibitor in development for the treatment of inflammatory bowel disease. FIL for the treatment of moderately to severely active ulcerative colitis (UC) was evaluated in… read more here.
Keywords: maintenance study; maintenance; fil 200; study ... See more keywords
OP25 Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab075.024
Abstract: Patients with ulcerative colitis (UC) often do not respond to treatment or lose response over time, and thus switch between therapies with various mechanisms of action (MoAs).1 Filgotinib (FIL) is a once-daily, oral, Janus kinase… read more here.
Keywords: fil 200; bio experienced; week; experienced patients ... See more keywords
THU0173 FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) BY RACE & GEOGRAPHIC REGION
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.2323
Abstract: Background Filgotinib (FIL), an oral, selective Janus kinase 1 (JAK1) inhibitor, significantly improved the signs and symptoms of rheumatoid arthritis (RA) in the phase 3 FINCH2 study in bDMARD-IR patients with active RA.1 Objectives To… read more here.
Keywords: fil; region; ltd; fil 200 ... See more keywords